Drug Trial Radar · NCT06784726
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Sep 4, 2025
Primary completion
Apr 10, 2028
Study completion Apr 11, 2033
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jan 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of improvement (relapsed) or that have not responded to previous treatment (refractory). Odronextamab is a bispecific antibody that can bind to two different antigens at the same time. Odronextamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Bridging therapy has been used to maintain disease control and to increase the chance of successful receipt of CAR-T cell therapy. However, bridging therapy is typically given after leukapheresis, which does not help prevent disease progression between the decision for CAR-T cell therapy and leukapheresis. Giving odronextamab as bridging therapy before leukapheresis may delay disease progression to allow leukapheresis and increase the likelihood of successful CAR-T cell therapy in patients with relapsed or refractory large B-cell lymphomas.
Conditions
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Grade 3b Follicular Lymphoma
- Recurrent High Grade B-Cell Lymphoma
- Recurrent Primary Mediastinal Large B-Cell Lymphoma
- Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory Grade 3b Follicular Lymphoma
- Refractory High Grade B-Cell Lymphoma
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
OdronextamabBiological
Given IV
Biospecimen CollectionProcedure
Undergo collection of blood and oral or rectal swab samples
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Chimeric Antigen Receptor T-Cell TherapyBiological
Undergo CAR-T cell therapy
Computed TomographyProcedure
Undergo PET/CT
LeukapheresisProcedure
Undergo leukapheresis
Lumbar PunctureProcedure
Undergo lumbar puncture
Positron Emission TomographyProcedure
Undergo PET/CT
Questionnaire AdministrationOther
Ancillary studies
Biopsy ProcedureProcedure
Undergo tissue biopsy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Failure to undergo leukapheresisTime frame: Up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.